Neuca

Neuca EBIT per Share

The EBIT per Share of Neuca (NEU.WA) as of Oct 21, 2026 is 49.75 PLN. In the previous year, EBIT per Share was 60.66 PLN — a change of -17.98% (lower).

EBIT per Share

49.75PLN

YoY

-17.98%

Last updated:

EBIT per Share of Neuca is 2025 49.75 PLN. EBIT per Share of Neuca was 2024 60.66 PLN. It decreases by -17.98% lower compared to the previous year.

The Neuca EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2024
60.66 PLN
Jan 1, 2025
49.75 PLN
Jan 1, 2026 (e)
78.58 PLN
Jan 1, 2027 (e)
87.37 PLN
Jan 1, 2028 (e)
97.22 PLN
Jan 1, 2029 (e)
124.92 PLN
Jan 1, 2030 (e)
91.23 PLN
Jan 1, 2031 (e)
0.00 PLN
The Neuca EBIT per Share history
YEAREBIT per ShareYoY
est0.00PLN-100.00%
est91.23PLN-26.96%
est124.92PLN+28.49%
est97.22PLN+11.28%
est87.37PLN+11.18%
est78.58PLN+57.96%
49.75PLN-17.98%
60.66PLN+3.64%
58.53PLN+8.64%
53.88PLN+23.86%
43.50PLN-10.69%
48.70PLN+31.11%
37.15PLN+30.81%
28.40PLN+8.84%
26.09PLN-17.35%
31.57PLN+17.22%
26.93PLN+58.23%
17.02PLN-25.03%
22.70PLN+7.05%
21.21PLN+20.80%
17.56PLN+22.02%
14.39PLN+17.86%
12.21PLN+50.38%
8.12PLN+53.44%
5.29PLN+80.08%
2.94PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

EBIT per Share of Neuca is 49.75 PLN in 2025.

EBIT per Share of Neuca changed from 60.66 PLN to 49.75 PLN, representing a -17.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Neuca since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neuca

All Key Metrics — Neuca